What is Zoster‑induced vision loss?
Zoster‑induced vision loss refers to visual impairment that occurs after infection with the varicella‑zoster virus (VZV), the same virus that causes chickenpox and shingles. When VZV reactivates in the cranial nerves or ocular tissues, it can produce a condition called **herpes zoster ophthalmicus (HZO)**. In HZO, the virus spreads along the ophthalmic branch of the trigeminal nerve (V1) and may involve the cornea, conjunctiva, sclera, retina, optic nerve, and surrounding structures. Damage to any of these ocular components can lead to partial or complete loss of vision, sometimes permanently if treatment is delayed.
Vision loss from zoster is not a single disease; it is a spectrum ranging from mild blurring or photophobia to severe keratitis, uveitis, retinal necrosis, or optic neuritis. Prompt recognition and antiviral therapy are essential to preserve sight and to reduce the risk of long‑term complications.
Common Causes
Vision loss associated with herpes zoster ophthalmicus can result from several distinct ocular pathologies. The most frequent causes include:
- Corneal keratitis – inflammation or ulceration of the cornea.
- Stromal keratitis – scarring in the corneal stroma that clouds the eye.
- Uveitis (anterior or posterior) – inflammation of the uveal tract.
- Retinal necrosis (progressive outer retinal necrosis, PORN) – rapid destruction of retinal tissue.
- Acute retinal necrosis (ARN) – severe inflammation and necrosis of the retina and vitreous.
- Optic neuritis – inflammation of the optic nerve leading to sudden visual acuity loss.
- Scleritis – painful inflammation of the sclera that can encroach on adjacent structures.
- Elevated intra‑ocular pressure (secondary glaucoma) – can damage the optic nerve.
- Orbital cellulitis / orbital abscess – spread of infection behind the eye causing compression.
- Neurotrophic keratopathy – loss of corneal sensation leading to ulceration and scarring.
Associated Symptoms
Patients with HZO‑related vision loss often experience a constellation of other ocular and systemic signs. Common accompanying symptoms include:
- Burning, tingling, or itching around the eye before the rash appears (prodrome).
- Redness of the eye (conjunctival injection).
- Sharp, stabbing eye pain that may worsen with eye movement.
- Photophobia (sensitivity to light).
- Blurred or hazy vision.
- Floaters or flashes of light, especially with retinal involvement.
- Swelling of the eyelids (ptosis) or drooping of the forehead skin (Hutchinson’s sign).
- Skin rash on the forehead, scalp, or eyelid following the V1 dermatome.
- General malaise, fever, or headache.
When to See a Doctor
Because vision loss can become irreversible within days, early medical evaluation is vital.
- If you notice any new eye pain, redness, or a rash on the forehead/eyelid.
- Sudden decrease in visual acuity, double vision, or a “curtain” coming across the field of view.
- Persistent photophobia or light sensitivity that interferes with daily activities.
- Development of halos around lights, floaters, or flashes.
- Any eyelid swelling, drooping, or facial weakness accompanying the eye symptoms.
- History of chickenpox or shingles in the past 6 months, especially if you are over age 50 or immunocompromised.
Even mild symptoms merit prompt evaluation by an ophthalmologist or an urgent‑care clinic that can assess ocular health.
Diagnosis
Diagnosis is a combination of clinical examination, imaging, and laboratory testing.
Clinical examination
- Slit‑lamp biomicroscopy – allows the doctor to view the cornea, anterior chamber, and iris for signs of keratitis or uveitis.
- Fundoscopic exam – evaluates the retina and optic nerve for necrosis, hemorrhage, or inflammation.
- Fluorescein staining – highlights corneal epithelial defects.
- Intra‑ocular pressure measurement – checks for secondary glaucoma.
Imaging
- Optical coherence tomography (OCT) – provides cross‑sectional images of the retina and optic nerve.
- Fundus photography – documents retinal lesions for follow‑up.
- Ultrasound B‑scan – useful if the view to the retina is blocked by inflammation or cataract.
Laboratory tests
- Polymerase chain reaction (PCR) of tear fluid or aqueous humor for VZV DNA (highly specific).
- Serologic testing for VZV IgM/IgG if the diagnosis is unclear.
- Complete blood count and metabolic panel in immunocompromised patients to guide antiviral dosing.
Treatment Options
The mainstay of therapy is antiviral medication, often combined with anti‑inflammatory agents and supportive care.
Medical therapies
- Systemic antivirals – Oral acyclovir (800 mg 5 × daily), valacyclovir (1 g 3 × daily), or famciclovir (500 mg 3 × daily) for 7–14 days. Intravenous acyclovir is reserved for severe retinal involvement or immunocompromised patients.
- Topical antivirals – Ganciclovir 0.15% or trifluridine eye drops for epithelial keratitis.
- Corticosteroids – Topical prednisolone acetate 1% for uveitis or keratitis, administered under close supervision to avoid increased intra‑ocular pressure.
- Cycloplegic agents – Homatropine or cyclopentolate to relieve ciliary spasm and prevent synechiae.
- Intra‑ocular pressure‑lowering drops – Timolol, apraclonidine, or prostaglandin analogues if glaucoma develops.
- Immunomodulators – For resistant necrotizing retinitis, intravitreal injections of ganciclovir or foscarnet may be used.
Home and supportive care
- Cold compresses to reduce eyelid swelling.
- Artificial tears or lubricating ointments to keep the cornea moist.
- Avoid rubbing the eyes; use clean hands when applying drops.
- Protect the eye from bright light with sunglasses.
- Maintain good nutrition and hydration to support immune recovery.
- Complete the full course of antivirals even if symptoms improve early.
Prevention Tips
Because HZO stems from reactivation of dormant VZV, prevention focuses on boosting immunity and vaccinating at‑risk populations.
- Shingles vaccine – Recombinant zoster vaccine (Shingrix) is >90 % effective in adults ≥50 years and is recommended even for those who have had shingles before.
- Maintain a healthy immune system – Adequate sleep, balanced diet, regular exercise, and controlling chronic conditions (diabetes, HIV, cancer) reduce reactivation risk.
- Prompt treatment of early shingles – Starting antiviral therapy within 72 hours of rash onset diminishes the chance of ocular involvement.
- Avoid close contact with individuals who have active shingles lesions, especially if you are immunocompromised.
- Regular eye examinations for people with a history of HZO, diabetes, or glaucoma.
Emergency Warning Signs
If any of the following occur, seek emergency medical attention (e.g., emergency department or ophthalmology on call) immediately.
- Sudden, severe loss of vision in one or both eyes.
- Rapidly worsening eye pain that does not improve with medication.
- Presence of a “black curtain” or shadow over part of the visual field.
- New onset of double vision (diplopia) or inability to move the eye.
- High fever (>38.5 °C / 101.3 °F) with rash spreading beyond the V1 dermatome.
- Signs of orbital cellulitis: swelling, redness, and warmth around the eye together with systemic toxicity.
- Sudden increase in intra‑ocular pressure causing headaches, nausea, or vomiting.
Key Take‑aways
Zoster‑induced vision loss is a serious but treatable complication of shingles affecting the eye. Early recognition of prodromal eye pain, rash in the V1 distribution, and any change in visual acuity can save sight. Antiviral therapy started within 72 hours, combined with appropriate anti‑inflammatory treatment, offers the best chance of preserving vision. Vaccination, good general health, and prompt care for shingles are essential preventive strategies.
References:
- Mayo Clinic. “Herpes Zoster Ophthalmicus.” https://www.mayoclinic.org
- Cleveland Clinic. “Eye Complications of Shingles.” https://my.clevelandclinic.org
- CDC. “Shingles (Herpes Zoster) Vaccination.” https://www.cdc.gov
- NIH – National Eye Institute. “Acute Retinal Necrosis.” https://www.nei.nih.gov
- World Health Organization. “Varicella‑zoster Virus.” https://www.who.int